NCI’s IMAT Program invites R33 applications to advance and rigorously validate innovative molecular and cellular analysis technologies that enhance cancer research and care. Projects must demonstrate prior feasibility, deliver transformative capabilities for targeting/probing cancer-relevant features, and include quantitative performance measures to drive adoption across basic, clinical, epidemiologic, and health-equity contexts. Clinical trials are not allowed.
Eligibility Criteria:
-
Eligible applicants: higher-education institutions; nonprofits; for-profits (including small businesses); local, state, tribal, and federal governments; independent school districts; public/tribal housing authorities; faith-/community-based and regional organizations; foreign organizations; and non-U.S. components of U.S. organizations.
-
Foreign components are allowed.
-
PD/PI must have an eRA Commons ID; organizational registrations required (SAM with UEI, Grants.gov, eRA Commons).
-
Applicant organizations may submit multiple scientifically distinct applications.
Funding Details:
-
Mechanism: R33 (Exploratory/Developmental Phase II).
-
Clinical trial: not allowed.
-
Budget: up to 300,000 USD in direct costs per year.
-
Project period: up to 3 years.
Deadline:
-
Due date: October 3, 2025, by 5:00 PM local time of applicant organization.
Where to go for further information:
-
Scientific contact: Kelly Crotty, Ph.D. — [email protected].
-
Peer review contact: Referral Officer — [email protected].
-
Grants management: Sean Hine — [email protected].
-
General help: eRA Service Desk; [email protected].